Physician profile
Kyle Washington
NPI 1952996548
$1,526.77
in general payments reported to CMS, 2019-2025
19 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $466 · 2023: $535 · 2024: $286 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $840 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $839.77 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $446.36 | 2023-2024 | Nuedexta, Rexulti |
| Astrazeneca Pharmaceuticals LP | $268.31 | 2022-2024 | Lokelma, Farxiga |
| Teva Pharmaceuticals USA, INC. | $202.18 | 2023-2025 | Austedo Xr, Austedo Xr |
| Glaxosmithkline, LLC. | $139.06 | 2021-2022 | |
| Abbvie INC. | $82.77 | 2022 | |
| Lilly USA, LLC | $58.19 | 2021-2022 | |
| Amgen INC. | $44.40 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $34.64 | 2023 | Nuplazid |
| Gilead Sciences, INC. | $32.85 | 2022 | |
| Novo Nordisk INC | $31.47 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.08 | 2022 | |
| Alkermes, INC. | $24.93 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $24.86 | 2022 | |
| Neurocrine Biosciences, INC. | $24.83 | 2023 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.56 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $18.80 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.65 | 2022 | |
| Lundbeck LLC | $15.74 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Washington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.